Atlas Trials

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Clinical trial NCT03945799 · TERMINATED

Trial details

NCT number
NCT03945799
Sponsor
Zhejiang University
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2019-04-22
Primary completion
2022-06-25
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.